What is endometrial cancer?

Reading time: 1 min

Endometrial cancer begins when the cells that line the inside of the uterus begin to grow out of control. In developed countries, it is the most frequent gynaecological cancer. In Spain, it is the fifth most common cancer in women.  

Endometrial cancer | PortalCLÍNIC
This type of tumour has a very good prognosis. The majority of patients, more than 85%, will be cured. The lifestyle they then lead will have a major influence on whether the disease returns or not, and whether they have a full and healthy life.

Endometrial cancer develops when the cells that line the inside of the uterus, known as the endometrium, begin to grow out of control. The endometrium is a tissue that is sensitive to female hormones, particularly oestrogen and progesterone. In women of childbearing age, it renews itself each month as part of the menstrual cycle.

In developed countries, endometrial cancer is the most frequent type of gynaecological cancer. In Spain, around 7,000–7,500 new cases are diagnosed each year, making it one of the most common cancers in women. In Spain, it is the fifth most common cancer among women (after breast, lung and colorectal and thyroid cancer). The average age at diagnosis is 63, and most cases are detected after the menopause, although the disease can appear earlier, particularly in women with risk factors.

Fortunately, about three out of four cases are detected at an early stage, when the tumour is confined to the uterus, and in these cases the five-year survival rate exceeds 90–95%. When diagnosed at a more advanced stage, the prognosis is more variable. However, recent advances in treatment have helped to improve survival.

How many people are affected?

Substantiated information by:

Published: 9 March 2022
Updated: 19 March 2026

The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.

Subscribe

Receive the latest updates related to this content.

Thank you for subscribing!

If this is the first time you subscribe you will receive a confirmation email, check your inbox

An error occurred and we were unable to send your data, please try again later.